This site is intended for US Healthcare Professionals

Clinical Data

I-REMOVE™ significantly reduced more body weight than placebo, without undesirable side effects1,2*

Up to 3X more weight loss than diet alone is possible when you recommend I-REMOVE™*

In a 12-week study, Litramine™ was evaluated in overweight and obese patients

In overweight patients,
  • At week 12, the overweight patients on Litramine™ lost an average of 7.89 lbs (3.58 kg) vs 2.07 lbs (0.94 kg) in the placebo group1*
  • At week 12, overweight patients on Litramine™ lost over 3X the weight as patients on placebo1

Mean Weight Loss1*

I-REMOVE™ reduced body weight up to 3x more than placebo

Overweight subgroup.

Mean Weight Loss Among Overweight Patients at 12 Weeks (lbs)1

Mean Weight Loss Among Obese Patients at 12 Weeks (lbs)

Mean Weight Loss Among Obese Patients at 12 Weeks (lbs)1

At week 12, the mean weight loss of patients on Litramine™ was over 3x as much as the placebo group.
Study Design

A multicenter, randomized, double-blind, placebo controlled study involving 125 overweight and obese patients. Subjects were advised on physical activity and received nutritional counseling, including hypocaloric diet. After a 2-week placebo run-in phase, patients were randomized to receive either 3 g/day Litramine™ or placebo. The primary endpoint was change in body weight from baseline. Secondary endpoints included additional obesity measures and safety parameters.

1 kg=2.2 lb.

............
Over 50% of patients on Litramine™ lost between 9 and 18 lbs. in 12 weeks.
  • Over 50% of patients lost between 9 and 18 lbs in 12 weeks3
  • 73% of overweight patients on Litramine™ lost ≥6 lbs3
  • More Litramine™ subjects lost at least 5% more of their initial body weight compared with placebo (P=0.027)1

Patients maintained weight loss with I-REMOVE™*

In a separate 6-month study, subjects on Litramine™ maintained reduction in body weight, waist and hip circumferences, and body fat mass, and lean body mass.3

.................... 92% of patients in the Litramine™ group maintained initial weight loss in a 6-month study.
  • 92% of subjects in the Litramine™ group were able to maintain their body weight after initial weight loss, versus 25% in the placebo group3
  • 60% of patients on Litramine™ reported an increased feeling of satiety over the study period vs 12.5% of patients on placebo (P<0.001)3
Study Design

A multicenter, double-blind, randomized, placebo-controlled trial on overweight and obese patients. Duration of study was 24 weeks. Patients with documented weight loss of 3% over the last 3-6 months were randomized to groups given Litramine™ (3 g/day) or a matching placebo. Primary endpoints were difference of mean body weight (kg) between baseline and end of study and maintenance of initially lost body weight, where maintenance is defined as ≤1% weight gain.

I-REMOVE™ with Litramine™ was well tolerated in both short-term
and long-term studies1,2

In a 12-week study:

95.2% of Litramine™-treated subjects completed this study, indicating that Litramine™ is safe and well tolerated1

.

No reports of GI side effects, such as oily spotting, abdominal pain, bloating, and constipation1

.

No significant changes or abnormalities in clinical laboratory parameters1

In a 6-month study:

Litramine™ was well tolerated by the subjects2

.

No serious or product-related adverse events were reported2

.

No significant changes or abnormalities in clinical laboratory parameters2

In a 12-week study:

95.2% of Litramine™-treated subjects completed this study, indicating that Litramine™ is safe and well tolerated1

No reports of GI side effects, such as oily spotting, abdominal pain, bloating, and constipation

No significant changes or abnormalities in clinical laboratory parameters

In a 6-month study:

Litramine™ was well tolerated by the subjects2

No serious or product-related adverse events were reported2

No significant changes or abnormalities in clinical laboratory parameters2

I-REMOVE™ is helping millions of patients worldwide lose weight, safely3*

28 million packs were sold worldwide

Over an 11-year period (2006-2017), only 0.003% (3/100,000) of patients have reported any product-related health complaints3*

References: 1. Grube B, Chong PW, Lau KZ, Orzechowski HD. A natural fiber complex reduces body weight in the overweight and obese: a double-blind, randomized, placebo-controlled study. Obesity (Silver Spring). 2013;21(1):58-64. 2. Grube B, Chong PW, Alt F, Uebelhack R. Weight maintenance with Litramine (IQP-G-002AS): A 24-week double-blind, randomized, placebo-controlled study. J Obes. 2015;2015:1-6. 3. Data on file. InQpharm.